ReviewJournal of diabetes research2015
Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.
Review in Journal of diabetes research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 127 citations in OpenAlex.
- Chitosan-Coated Niosomal Nanocarriers for the Co-Delivery of Glibenclamide and Curcumin in Diabetes Mellitus.Polymers · 2026Article
- Emerging Breakthroughs in Nano-Ginseng Innovations and Their Therapeutic Implications in Type 2 Diabetes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Structure-activity Relationship (SAR) Insight for the Most Effective Oral Antidiabetic Compounds-A Current Review.Current topics in medicinal chemistry · 2026Review
- (D-AlaInternational journal of molecular sciences · 2025Article
- New 5,6-diphenyl-1,2,4-triazine-hydrazineylidene-phenoxy-1,2,3-triazole-acetamide derivatives as potent synthetic α-glucosidase inhibitors.RSC advances · 2025Article
- Fenugreek seeds as a natural source of L-arginine-encapsulated lipid nanoparticles against diabetes.Scientific reports · 2025Article
- Screening of antihyperglycemic and cytotoxic properties ofIn silico pharmacology · 2025Article
- In silico analysis of Rutin and Morin against diabetes-associated molecular targets.In silico pharmacology · 2025Article
- Nanotechnology-Based Approaches for the Management of Diabetes Mellitus: An Innovative Solution to Long-Lasting Challenges in Antidiabetic Drug Delivery.Pharmaceutics · 2024Review
- Exploration of the Topical Nanoemulgel Bearing with Ferulic Acid and Essential Oil for Diabetic Wound Healing.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Article
- Article
- The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.Biological research · 2024Article
- Article
- The emerging role of medical foods and therapeutic potential of medical food-derived exosomes.Nanoscale advances · 2023Review
- Fractionation, identification of chemical constituents, and biological properties of cashew (Food science & nutrition · 2023Article
- In vitro and in vivo antioxidant and antihyperglycemic potentials of phenolic fractions ofFood science & nutrition · 2023Article
- The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Particle-Based therapies for antigen specific treatment of type 1 diabetes.International journal of pharmaceutics · 2023Review
- Effectiveness of Journal Club Presentation as a Learning Modality in the Endocrinology and Endocrine Surgery Module in an Integrative Undergraduate Medical Curriculum.Advances in medical education and practice · 2023Article
- A Mini-Review of Current Treatment Approaches and Gene Therapy as Potential Interventions for Diabetes Mellitus Types 1.Advanced biomedical research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes highlights a growing epidemic imposing serious social economic crisis to the countries around the globe. Despite scientific breakthroughs, better healthcare facilities, and improved literacy rate, the disease continues to burden several sections, especially middle and low income countries. The present trends indicate the rise in premature death, posing a major threat to global development. Scientific and technological advances have witnessed the development of newer generation of drugs like sulphonylureas, biguanides, alpha glucosidase inhibitors, and thiazolidinediones with significant efficacy in reducing hyperglycemia. Recent approaches in drug discovery have contributed to the development of new class of therapeutics like Incretin mimetics, Amylin analogues, GIP analogs, Peroxisome proliferator activated receptors, and dipeptidyl peptidase-4 inhibitor as targets for potential drugs in diabetes treatment. Subsequently, the identification and clinical investigation of bioactive substances from plants have revolutionized the research on drug discovery and lead identification for diabetes management. With a focus on the emerging trends, the review article explores the current statistical prevalence of the disease, discussing the benefits and limitations of the commercially available drugs. Additionally, the critical areas in clinical diabetology are discussed, with respect to prospects of statins, nanotechnology, and stem cell technology as next generation therapeutics and why the herbal formulations are consistently popular choice for diabetes medication and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.